CRMD PE Ratio & Valuation,Is CRMD Overvalued

CRMD Relative Valuation

CRMD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CRMD is overvalued; if below, it's undervalued.

Historical Valuation

CorMedix Inc (CRMD) is now in the Undervalued zone, suggesting that its current forward PS ratio of 1.85 is considered Undervalued compared with the five-year average of -4.90. The fair price of CorMedix Inc (CRMD) is between 226.01 to 239.91 according to relative valuation methord. Compared to the current price of 11.07 USD , CorMedix Inc is Undervalued By 95.1%.

Relative Value

Fair Zone

226.01-239.91

Current Price：11.07

95.1%

Undervalued

4.11

3.59

EV/EBITDA

CorMedix Inc. (CRMD) has a current EV/EBITDA of 3.59. The 5-year average EV/EBITDA is 1.09. The thresholds are as follows: Strongly Undervalued below -13.50, Undervalued between -13.50 and -6.20, Fairly Valued between 8.38 and -6.20, Overvalued between 8.38 and 15.67, and Strongly Overvalued above 15.67. The current Forward EV/EBITDA of 3.59 falls within the Historic Trend Line -Fairly Valued range.

4.01

EV/EBIT

CorMedix Inc. (CRMD) has a current EV/EBIT of 4.01. The 5-year average EV/EBIT is -8.14. The thresholds are as follows: Strongly Undervalued below -76.86, Undervalued between -76.86 and -42.50, Fairly Valued between 26.21 and -42.50, Overvalued between 26.21 and 60.57, and Strongly Overvalued above 60.57. The current Forward EV/EBIT of 4.01 falls within the Historic Trend Line -Fairly Valued range.

1.85

CorMedix Inc. (CRMD) has a current PS of 1.85. The 5-year average PS is 4094.64. The thresholds are as follows: Strongly Undervalued below -24251.09, Undervalued between -24251.09 and -10078.23, Fairly Valued between 18267.51 and -10078.23, Overvalued between 18267.51 and 32440.37, and Strongly Overvalued above 32440.37. The current Forward PS of 1.85 falls within the Historic Trend Line -Fairly Valued range.

3.47

P/OCF

CorMedix Inc. (CRMD) has a current P/OCF of 3.47. The 5-year average P/OCF is 5.97. The thresholds are as follows: Strongly Undervalued below -68.28, Undervalued between -68.28 and -31.16, Fairly Valued between 43.09 and -31.16, Overvalued between 43.09 and 80.21, and Strongly Overvalued above 80.21. The current Forward P/OCF of 3.47 falls within the Historic Trend Line -Fairly Valued range.

3.50

P/FCF

CorMedix Inc. (CRMD) has a current P/FCF of 3.50. The 5-year average P/FCF is 6.03. The thresholds are as follows: Strongly Undervalued below -68.77, Undervalued between -68.77 and -31.37, Fairly Valued between 43.43 and -31.37, Overvalued between 43.43 and 80.84, and Strongly Overvalued above 80.84. The current Forward P/FCF of 3.50 falls within the Historic Trend Line -Fairly Valued range.

CorMedix Inc (CRMD) has a current Price-to-Book (P/B) ratio of 2.41. Compared to its 3-year average P/B ratio of 5.01 , the current P/B ratio is approximately -51.99% higher. Relative to its 5-year average P/B ratio of 4.43, the current P/B ratio is about -45.62% higher. CorMedix Inc (CRMD) has a Forward Free Cash Flow (FCF) yield of approximately 8.22%. Compared to its 3-year average FCF yield of -11.00%, the current FCF yield is approximately -174.72% lower. Relative to its 5-year average FCF yield of -11.49% , the current FCF yield is about -171.54% lower.

2.41

P/B

Median3y

5.01

Median5y

4.43

8.22

FCF Yield

Median3y

-11.00

Median5y

-11.49

Competitors Valuation Multiple

The average P/S ratio for CRMD's competitors is 156.52, providing a benchmark for relative valuation. CorMedix Inc Corp (CRMD) exhibits a P/S ratio of 1.85, which is -98.82% above the industry average. Given its robust revenue growth of 810.22%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of CRMD increased by 41.85% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 11.46M to 104.28M.

The secondary factor is the P/E Change, contributed -238.87%to the performance.

Overall, the performance of CRMD in the past 1 year is driven by Revenue Growth. Which is more sustainable.

810.22%

11.46M → 104.28M

Revenue Growth

-529.50%

-24.24 → 104.11

Margin Expansion

-238.87%

-3.68 → 5.10

P/E Change

41.85%

8.10 → 11.49

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is CorMedix Inc (CRMD) currently overvalued or undervalued?

What is CorMedix Inc (CRMD) fair value?

CRMD's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of CorMedix Inc (CRMD) is between 226.01 to 239.91 according to relative valuation methord.

How does CRMD's valuation metrics compare to the industry average?

What is the current P/B ratio for CorMedix Inc (CRMD) as of Dec 15 2025?

As of Dec 15 2025, CorMedix Inc (CRMD) has a P/B ratio of 2.41. This indicates that the market values CRMD at 2.41 times its book value.

What is the current FCF Yield for CorMedix Inc (CRMD) as of Dec 15 2025?

As of Dec 15 2025, CorMedix Inc (CRMD) has a FCF Yield of 8.22%. This means that for every dollar of CorMedix Inc’s market capitalization, the company generates 8.22 cents in free cash flow.

What is the current Forward P/E ratio for CorMedix Inc (CRMD) as of Dec 15 2025?

As of Dec 15 2025, CorMedix Inc (CRMD) has a Forward P/E ratio of 4.11. This means the market is willing to pay $4.11 for every dollar of CorMedix Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for CorMedix Inc (CRMD) as of Dec 15 2025?

As of Dec 15 2025, CorMedix Inc (CRMD) has a Forward P/S ratio of 1.85. This means the market is valuing CRMD at $1.85 for every dollar of expected revenue over the next 12 months.

CRMD Valuation